The DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index; 88 of the 124 sources its claims cite were checked for support.
Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies
Open accessAbstract
Various factors are known to contribute to the diversity of human induced pluripotent stem cells (hiPSCs). Among these are the donor’s genetic background and family history, the somatic cell source, the iPSC reprogramming method, and the culture system of choice. Moreover, variability is seen even in iPSC clones, generated in a single reprogramming event, where the donor, somatic cell type, and reprogramming platform are the same. The diversity seen in iPSC lines often translates to epigenetic differences, as well as to differences in the expansion rate, iPSC line culture robustness, and their ability to differentiate into specific cell types. As such, the diversity of iPSCs presents a hurdle to standardizing iPSC-based cell therapy manufacturing. In this review, we will expand on the various factors that impact iPSC diversity and the strategies and tools that could be taken by the industry to overcome the differences amongst various iPSC lines, therefore enabling robust and reproducible iPSC-based cell therapy manufacturing processes.
Overview
CoChat Summary
TL;DR
This review argues that human induced pluripotent stem cell (hiPSC) diversity—arising from donor genetics, somatic cell source, reprogramming method, culture conditions, and even interclonal variation—is a central hurdle to standardizing iPSC-based cell therapy manufacturing. It surveys strategies such as defined media, automation, 3D bioreactor culture, and analytics to make manufacturing more robust and reproducible.
Key findings
- iPSC lines differ due to donor genetic background, somatic cell type, reprogramming method, and culture system; variability persists even among clones from a single reprogramming event (same donor, cell type, and platform).
- Donor effects: in a study of 194 healthy donors (101 female, 93 male), transcriptomic and proteomic profiling showed variability in CD41 and CD42a expression in iPSC-derived megakaryocytes, with differences by sex and race but not age. Reprogramming efficiency of adult fibroblasts was lower than newborn fibroblasts with a four-factor synthetic self-replicating RNA method, and could be improved by adding a fifth transcription factor.
- Somatic cell source: comparing 696 hiPSCs and daughter subclones, about 72% had genomic heterogeneity due to UV-related damage, indicating skin fibroblast-derived iPSCs harbor more pre-existing mutations than blood-derived iPSCs.
- Reprogramming method: chemical reprogramming of human somatic cells initially took 50 days with 0.2–2.5% efficiency, later optimized to 16 days with small-molecule boosters. Culture conditions (enzymatic vs. mechanical passaging, feeder-free vs. feeder-dependent) affect growth rate, genetic instability, and OCT4-positive cells in teratomas.
- Of 19 published hiPSC therapeutic trials cited (end of 2021), 15 (79%) were allogeneic and 4 autologous.
Methods
This is a narrative review; no primary data were generated. It synthesizes published literature on iPSC variability and manufacturing standardization, citing specific studies (e.g., Kammers et al., Yoshioka et al., Rouhani et al., Laurent et al., Mayshar et al., Paull et al., Bando et al., Konagaya et al., Tristan et al., Elanzew et al., Pandey et al.) to illustrate donor, somatic cell, reprogramming, culture, automation, 3D culture, and analytics considerations.
Limitations
The paper does not present a formal limitations section. Evident from the text: it is a review without systematic search or meta-analysis, so selection of cited studies may be non-exhaustive; several cited findings (e.g., donor sex/race effects, UV-related heterogeneity) come from individual studies whose generalizability is not assessed; and the authors note that automated systems in 2D and 3D for combined iPSC generation, expansion, and differentiation "has remained unexplored," and that industrial manufacturing has not yet fully adopted an integrated automated system.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
52 Valid · 3 Not valid · 13 Not checked · 17 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“To circumvent this problem, one group published the derivation of endothelial progenitor cells from PBMNCs, followed by reprogramming this cell population to iPSCs by mRNA reprogramming [38].”
§ Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies > 1. Introduction > 1.1. Not All iPSC Lines Are Created Equally
What the sources say
- Disputedcites [38] Zhou, 2009, Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins, Cell Stem Cell. sourceExperimental — accuracy not yet measured
The paper’s main text (page unavailable) reports reprogramming murine embryonic fibroblasts with recombinant proteins. That contradicts the cited sentence’s account of deriving endothelial progenitor cells from PBMNCs and reprogramming them with mRNA. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Yoshioka et al. found that by using four reprogramming factors of synthetic self-replicating RNA, the reprogramming efficiency of adult fibroblasts ended up lower than that of newborn fibroblasts [2].”
§ Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies > 1. Introduction > 1.1. Not All iPSC Lines Are Created Equally
What the sources say
- Partly supportedcites [2] Yoshioka, 2013, Efficient generation of human iPSCs by a synthetic self-replicative RNA, Cell Stem Cell. sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports that a synthetic self-replicating RNA expressing four reprogramming factors generated iPS cells from both newborn and adult human fibroblasts. It does not state that reprogramming efficiency was lower in adult fibroblasts, so the claimed comparison is unsupported by our copy. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The authors were able to increase the reprogramming efficiency of adult fibroblasts by adding an additional transcription factor to the reprogramming cocktail [3]”
§ Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies > 1. Introduction > 1.1. Not All iPSC Lines Are Created Equally
What the sources say
- Supportedcites [3] Yoshioka, N., and Dowdy, S.F. (2017). Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA. PLoS ONE, 12. source
The Introduction says the authors added reprogramming factors to a four-factor RNA construct and found that the five-factor version significantly increased iPSC generation in six adult human fibroblast samples. The Discussion likewise reports increased generation compared with the four-factor constructs, especially in older adult fibroblasts. Page numbers are not provided in our copy. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“implying that a reprogramming method might need optimization to successfully reprogram adult somatic cells.”
§ Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies > 1. Introduction > 1.1. Not All iPSC Lines Are Created Equally
What the sources say
- Supportedcites [3] Yoshioka, N., and Dowdy, S.F. (2017). Enhanced generation of iPSCs from older adult human cells by a synthetic five-factor self-replicative RNA. PLoS ONE, 12. source
The Introduction reports that reprogramming efficiency varied with cell source and age, and that adding a fifth factor significantly improved iPSC generation from adult human fibroblasts. The Discussion likewise says the original four-factor method had unacceptable efficiency in older adult fibroblasts. These findings support the hedged claim that a method might need optimization. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Skin fibroblasts are more prone to acquire additional DNA damage compared to blood cells as a result of the continuous exposure of skin to environmental stress, such as UV irradiation.”
§ Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies > 1. Introduction > 1.1. Not All iPSC Lines Are Created Equally
What the sources say
- Supportedcites [16] Rouhani, 2022, Substantial somatic genomic variation and selection for BCOR mutations in human induced pluripotent stem cells, Nat. Genet. source
In Results, “Genomic variations in skin and blood derived hiPSCs” (page not provided), fibroblast-derived hiPSCs had more mutations than blood-derived hiPSCs, and the authors attribute their UV-related damage to sunlight exposure in vivo. Results, “Substantial genomic heterogeneity between F-hiPSCs clones,” also identifies UV-consistent mutations in the parental skin fibroblasts. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
42 more claims · 28 with their cited sources checked
Create a free account to see all 85 claims and every source verdict.
- It may state two separate claims as one. 26
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reprogramming and differentiation can introduce line-to-line variability, clonal differences, and heterogeneity in differentiation efficiency, which may affect reproducibility and functional interpretation (Volpato and Webber 2020;Nath et al. 2023).”
From Primary cell cultures versus immortalized cell lines: critical comparative insights into biological fidelity and translational applications (2026) · cites this paper as Nath et al. 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies > 1. Introduction > 1.1. Not All iPSC Lines Are Created Equally
“To circumvent this problem, one group published the derivation of endothelial progenitor cells from PBMNCs, followed by reprogramming this cell population to iPSCs by mRNA reprogramming [38].”
§ Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies > References
“38. Zhou H. Wu S. Joo J.Y. Zhu S. Han D.W. Lin T. Trauger S. Bien G. Yao S. Zhu Y. Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins Cell Stem Cell. 2009 4 381 384 10.1016/j.stem.2009.04.005 19398399 PMC10182564”
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Human induced pluripotent stem cells free of vector and transgene sequences
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I. I., & Thomson, J. A. (2009) · Science · doi:10.1126/science.1172482 · Cited by 2,386 · cited 2×
“Another example of a non-integrative cellular reprogramming technique is episomal-based reprogramming, which relies on a one-time introduction of episomal DNA plasmid vectors encoding reprogramming-inducing transcription factors [34–36].”
BackgroundGeneration of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins
Kim, D., Kim, C.-H., Moon, J.-I., Chung, Y.-G., Chang, M.-Y., Han, B.-S., Ko, S., Yang, E., Cha, K. Y., Lanza, R., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.05.005 · Cited by 1,814 · cited 1×
“Another method for reprogramming relies on the delivery of the transcription factors in their protein form [39–41].”
MethodpiggyBac transposition reprograms fibroblasts to induced pluripotent stem cells
Woltjen, K., Michael, I. P., Mohseni, P., Desai, R., Mileikovsky, M., Hämäläinen, R., Cowling, R., Wang, W., Liu, P., Gertsenstein, M., et al. (2009) · Nature · doi:10.1038/nature07863 · Cited by 1,814 · cited 1×
“Such techniques could be combined with the non-viral transfer system that uses a mobile genetic element, e.g., PiggyBac transposons [20–22].”
BackgroundGeneration of Induced Pluripotent Stem Cells Using Recombinant Proteins
Zhou, H., Wu, S., Joo, J. Y., Zhu, S., Han, D. W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.04.005 · Cited by 1,788
Induced pluripotent stem cells generated without viral integration
Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., & Hochedlinger, K. (2008) · Science · doi:10.1126/science.1162494 · Cited by 1,683 · cited 1×
“Adenovirus and Sendai virus-mediated vector delivery provide alternative non-integrative methods for iPSC reprogramming [24–28].”
Chemically defined conditions for human iPSC derivation and culture
Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1593 · Cited by 1,447
Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes
Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A., Gonzalez, F., Vassena, R., Bilić, J., Pekarik, V., Tiscornia, G., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1503 · Cited by 1,423
FUSAKI, N., BAN, H., NISHIYAMA, A., SAEKI, K., & HASEGAWA, M. (2009) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.85.348 · Cited by 1,411
Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds.
Hou, P., Li, Y., Zhang, X., Liu, C., Guan, J., Li, H., Zhao, T., Ye, J., Yang, W., Liu, K., et al. (2013) · Science · doi:10.1126/science.1239278 · Cited by 1,402 · cited 1×
“Chemical programming is an attractive “zero-footprint” reprogramming method for clinical-grade iPSC generation [42–44]; however, most of the chemical reprogramming methods developed so far have used mouse cells because of their stable epigenome and high plasticity compared to human cells [45–48].”
Background
Cited by
Automated manufacturing of cell therapies
Melocchi, A., Schmittlein, B., Sadhu, S., Nayak, S., Lares, A., Uboldi, M., Zema, L., di Robilant, B. N., Feldman, S. A., & Esensten, J. H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.057 · Cited by 53
Stem Cells in Bone Tissue Engineering: Progress, Promises and Challenges
Augustine, R., Gezek, M., Nikolopoulos, V. K., Buck, P. L., Bostancı, N. S., & Camci‐Unal, G. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10738-y · Cited by 44
Joshi, J., Albers, C., Smole, N., Guo, S., & Smith, S. A. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1475152 · Cited by 33
“…reprogramming methods, 3) culture conditions, and 4) clonal variations in iPSCs derived from the same donor and generated under the same reprogramming event, all which affects their pluripotency, differentiation potential and phenotypic characteristics (Han and Entcheva, 2023; Nath et al., 2023).”
BackgroundAdopting Mechanistic Molecular Biology Approaches in Exposome Research for Causal Understanding
Foreman, A., Warth, B., Hessel, E. V. S., Price, E. J., Schymanski, E., Cantelli, G., Parkinson, H., Hecht, H., Klánová, J., Vlaanderen, J. J., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.3c07961 · Cited by 31
“89 In the past decade, advances in molecular biology have led to the development of a range of tools and high-throughput methods that have allowed the adoption of molecular techniques in the laboratory analysis of environmental exposure risk.”
BackgroundJiang, Q., Yu, W., Ma, J., Zhao, M., Zou, J., Mir, S. A., Zhang, J., Germain, R. N., & Hassan, R. (2025) · Science Advances · doi:10.1126/sciadv.adt9932 · Cited by 23
“Thus, iPSC line diversity also poses challenges for standardizing cell manufacturing processes for iPSC-based therapies ( 8 ).”
Metadata
- Authors
- Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I.
- Affiliations
- Lonza (United States) (US)
- Cell Therapy Process Department, Lonza Inc., Houston, TX 77047, USA
- Cell Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA
- ORCID
- Nath, Suman C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2023-11-29
- Volume
- 24
- Issue
- 23
- Pages
- 16929
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10706975
- OpenAlex
- W4389137472
- Semantic Scholar
- 8863966fefda90897ca1bbf1378dd8b6a2993f59
- Cited by
- 35
- References
- 86
- Citations by year
- 2026: 19 · 2025: 10 · 2024: 6
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- induced pluripotent stem cells, cell therapy manufacturing, epigenetic variation, differentiation potential
- MeSH terms
- Cell Differentiation, Humans, Epigenesis, Genetic, Induced Pluripotent Stem Cells, Cell- and Tissue-Based Therapy, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies. https://app.cochat.ai/papers/10.3390/ijms242316929
- The paper
- Nath, S. C., Menendez, L., & Friedrich Ben-Nun, I. (2023). Overcoming the Variability of iPSCs in the Manufacturing of Cell-Based Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242316929
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.